A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)

NCT02386072 · clinicaltrials.gov ↗

COMPLETED

Status

1524

Enrollment

INDUSTRY

Sponsor class

Conditions

Urinary Bladder Overactive
Overactive Bladder
Urinary Bladder Diseases
Urologic Diseases

Interventions

DRUG: mirabegron
DRUG: antimuscarinic medication

Sponsor

Astellas Scientific & Medical Affairs, Inc.